PriceTargets.com logo

Caribou Biosciences - CRBU Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $10.20
  • Forecasted Upside: 425.77%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$1.94 As of 12/17/2024 01:00 AM ET
▲ +0.03 (1.57%)

This chart shows the closing price for CRBU by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Caribou Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRBU and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRBU

Analyst Price Target is $10.20
▲ +425.77% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Caribou Biosciences in the last 3 months. The average price target is $10.20, with a high forecast of $19.00 and a low forecast of $3.00. The average price target represents a 425.77% upside from the last price of $1.94.

This chart shows the closing price for CRBU for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in Caribou Biosciences. This rating has held steady since October 2024, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/27/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/25/2023
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/24/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/23/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/21/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/19/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/18/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/18/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/26/2024CitigroupLower TargetBuy ➝ Buy$30.00 ➝ $6.00
11/15/2024HC WainwrightReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
9/3/2024HC WainwrightReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
8/14/2024HC WainwrightReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
8/7/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$14.00 ➝ $14.00
7/17/2024HC WainwrightReiterated RatingBuy ➝ Buy$9.00 ➝ $9.00
6/4/2024HC WainwrightLower TargetBuy ➝ Buy$24.00 ➝ $9.00
6/3/2024Evercore ISIDowngradeOutperform ➝ Inline$13.00 ➝ $3.00
5/16/2024Truist FinancialReiterated RatingBuy ➝ Buy$19.00 ➝ $19.00
5/13/2024HC WainwrightReiterated RatingBuy ➝ Buy$24.00
3/19/2024HC WainwrightBoost TargetBuy ➝ Buy$23.00 ➝ $24.00
11/8/2023Cantor FitzgeraldInitiated CoverageNeutral
10/31/2023Evercore ISIInitiated CoverageOutperform$13.00
9/5/2023CitigroupLower Target$37.00 ➝ $30.00
7/26/2023HC WainwrightLower TargetBuy$25.00 ➝ $23.00
7/11/2023Truist FinancialInitiated CoverageBuy ➝ Buy$23.00
5/10/2023HC WainwrightLower Target$26.00 ➝ $25.00
3/17/2023Bank of AmericaLower Target$27.00 ➝ $25.00
3/14/2023HC WainwrightLower TargetBuy$27.00 ➝ $26.00
3/10/2023Royal Bank of CanadaReiterated RatingOutperform$19.00
3/10/2023OppenheimerLower TargetOutperform$36.00 ➝ $32.00
11/23/2022CitigroupLower Target$38.00 ➝ $37.00
8/29/2022CitigroupLower TargetBuy$39.00 ➝ $38.00
8/18/2022HC WainwrightLower TargetBuy$28.00 ➝ $27.00
5/12/2022CitigroupBoost Target$29.00 ➝ $39.00
5/12/2022Leerink PartnersBoost Target$30.00 ➝ $34.00
3/22/2022Leerink PartnersLower TargetOutperform$32.00 ➝ $29.00
2/17/2022Royal Bank of CanadaInitiated CoverageOutperform$22.00
2/14/2022Brookline Capital AcquisitionInitiated CoverageBuy$19.00
2/14/2022Brookline Capital ManagementReiterated RatingBuy
11/30/2021OppenheimerInitiated CoverageOutperform$36.00
11/30/2021HC WainwrightInitiated CoverageBuy$28.00
11/12/2021CitigroupUpgradeNeutral ➝ Buy$27.00
8/17/2021Leerink PartnersInitiated CoverageOutperform$32.00
8/17/2021Bank of AmericaInitiated CoverageBuy$30.00
8/17/2021CitigroupInitiated CoverageNeutral$27.00
(Data available from 12/18/2019 forward)

News Sentiment Rating

0.49 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/22/2024
  • 2 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
6/21/2024
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/21/2024
  • 2 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/20/2024
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/19/2024
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/19/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
11/18/2024
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/18/2024

Current Sentiment

  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Caribou Biosciences logo
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Read More

Today's Range

Now: $1.94
Low: $1.85
High: $1.95

50 Day Range

MA: $2.09
Low: $1.77
High: $2.79

52 Week Range

Now: $1.94
Low: $1.50
High: $8.33

Volume

1,200,232 shs

Average Volume

1,697,278 shs

Market Capitalization

$175.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.27

Frequently Asked Questions

What sell-side analysts currently cover shares of Caribou Biosciences?

The following sell-side analysts have issued research reports on Caribou Biosciences in the last twelve months: Citigroup Inc., Evercore ISI, HC Wainwright, Royal Bank of Canada, and Truist Financial Co..
View the latest analyst ratings for CRBU.

What is the current price target for Caribou Biosciences?

0 Wall Street analysts have set twelve-month price targets for Caribou Biosciences in the last year. Their average twelve-month price target is $10.20, suggesting a possible upside of 425.8%. Truist Financial Co. has the highest price target set, predicting CRBU will reach $19.00 in the next twelve months. Evercore ISI has the lowest price target set, forecasting a price of $3.00 for Caribou Biosciences in the next year.
View the latest price targets for CRBU.

What is the current consensus analyst rating for Caribou Biosciences?

Caribou Biosciences currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CRBU will outperform the market and that investors should add to their positions of Caribou Biosciences.
View the latest ratings for CRBU.

What other companies compete with Caribou Biosciences?

Other companies that are similar to Caribou Biosciences include Arbutus Biopharma, Entrada Therapeutics, Prothena, Tectonic Therapeutic and CARGO Therapeutics. Learn More about companies similar to Caribou Biosciences.

How do I contact Caribou Biosciences' investor relations team?

The company's listed phone number is 510-982-6030 and its investor relations email address is [email protected]. The official website for Caribou Biosciences is cariboubio.com. Learn More about contacing Caribou Biosciences investor relations.